In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $52.06, marking a +2.1% move from the previous day. This change outpaced the S&P 500's 0.49% loss on the day. Elsewhere, the Dow ...

CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.

CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the ...

Tue, March 17, 2026 at 4:16 PM UTC The catalyst behind Piper Sandler's revised target is a freshly issued $600M convertible note due March 2031, convertible at $76.56 per share with an effective ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11, 2026.

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even come ...